Thank you to the many participants who joined the EANO–SNO Highlights Webinar 2025! Outstanding talks, engaging discussion, and key scientific insights from #EANO2025 & #SNO2025.

🎥 The full recording is now online on our YouTube channel – watch or rewatch anytime!

👉 youtu.be/REdE1Y8zQZQ?...

📣 Join the 4th Annual EANO/SNO Highlights Webinar
Top abstracts from #EANO2025 (Prague) & #SNO2025 (Honolulu) – latest advances in neuro-oncology.
🗓 Feb 6, 2026 | ⏰ 18:30–19:30 CET
🎟 Free for #EANO & #SNO members
👉 Register now: bit.ly/EANO-SNO-2025
#NeuroOncology @neuroonc.bsky.social

final O'ahu sunset at #SNO2025 before returning back to @stanfordbraintumor.bsky.social to continue in our collaborative quest to cure brain tumors

So much exciting progress in the fight against #BrainTumors presented at this year's Society for Neuro-Oncology Annual Meeting #SNO2025. Thanks to all the incredible @neuroonc.bsky.social staff and colleagues around the world for putting this conference together! Looking forward to #SNO2026

Thanks to support from the Gilbert Family Foundation's Curing Neurofibromatosis program, we are now building the first single cell atlas of NF1-associated gliomas spanning the different molecular subtypes & also both pre- and post-treatment tumors #SNO2025
gilbertfamilyfoundation.org/curing-neuro...

Copanlisib/Ibrutinib Data Highlight Potential for PI3K Inhibition in R/R PCNSL | OncLive BTK and PI3K inhibition produced responses but unexpected PK data in relapsed/refractory PCNSL.

Copanlisib/Ibrutinib Data Highlight Potential for PI3K Inhibition in R/R PCNSL #SNO2025 #lymsm #oncology www.onclive.com/view/copanli...

This month literally flew by! First, a trip to Spain to present our spatial-omics work on #glioblastoma #gbm at #Cancers2025, then all the way back to New Mexico & a trip to Hawaii for #sno2025! It was great to catch up with old colleagues/friends & establish new collaborations!

That’s a wrap on WFNOS/SNO 2025 in Honolulu, Hawaii!
The #EANO team truly enjoyed connecting with colleagues from around the world, exchanging insights, and celebrating SNO’s 30th anniversary. A big thank you to the @neuroonc.bsky.social for hosting this inspiring meeting! 🌺

#SNO2025 #WFNOS2025

Back to cold Vienna 🥶 after #SNO2025 #WFNOS2025 in Honolulu! 🌺🏝️
Great talks, inspiring discussions, presenting own data, catching up with friends & colleagues - all made even better by Hawaiian sunshine. 😎
Last conference of 2025 in the books. Looking forward to what’s next in 2026! 🚀 #btsm

The lab was well represented at #SNO2025 in Honolulu spanning 4 presentations. Congratulations, team! @neurosurgucsf.bsky.social @ucsfradonc.bsky.social

Very proud and truly honored to have taken part in this year’s SNO in Hawaii. Inspiring science, outstanding discussions, and my incredible lab pushing the boundaries @milolab.bsky.social Grateful for the beautiful setting that made this meeting unforgettable #SNO2025 #KeynoteSpeaker #NeuroOncology

Vorasidenib Shows Rapid Real-World Uptake in IDH-Mutated Glioma | OncLive Vorasidenib is being integrated in the real-world setting for the treatment of patients with IDH-mutated glioma.

Vorasidenib Shows Rapid Real-World Uptake in IDH-Mutated Glioma @neuroonc.bsky.social #SNO2025 #oncology #glioma
www.onclive.com/view/vorasid...

Eflornithine Plus Lomustine Extends PFS, OS in Reclassified WHO Grade 3 IDH-Mutated Astrocytoma | OncLive Eflornithine plus lomustine produced superior OS and PFS outcomes vs lomustine in WHO grade 3 IDH-mutated astrocytoma.

Eflornithine Plus Lomustine Extends PFS, OS in Reclassified WHO Grade 3 IDH-Mutated Astrocytoma @huntsmancancer.bsky.social #SNO2025 #btsm #oncology www.onclive.com/view/eflorni...

Temozolomide Plus Radiotherapy Yields Survival Benefit in IDH-Mutant LGG | OncLive Temozolomide plus radiotherapy significantly improved OS vs radiotherapy alone in IDH-mutant low-grade gliomas without codeletions of 1q and 19q.

Temozolomide Plus Radiotherapy Yields Survival Benefit in IDH-Mutant LGG @neuroonc.bsky.social #SNO2025 #oncology
www.onclive.com/view/temozol...

Aloha from #SNO2025 from #Zoulab @labfriedel.bsky.social
🌴

Mirdametinib Shows Improved ORR Over Time in NF1-Associated Symptomatic Plexiform Neurofibroma | OncLive Long-term ReNeu results showed deeper, more durable responses to mirdametinib in NF1-PN with extended treatment in both adults and children.

Mirdametinib Shows Improved ORR Over Time in NF1-Associated Symptomatic Plexiform Neurofibroma #SNO2025 #oncology www.onclive.com/view/mirdame...

Amazing Keynote talk by @heilandhenrik.bsky.social on "Translational Data Integration and Technological Developments in Neuro-Oncology" at the ongoing #SNO2025 in Hawaii.🧠

Regorafenib Plus Temozolomide and RT Shows Early Signs of Tolerability in MGMT-Methylated, IDH Wild-Type Glioblastoma | OncLive The RP2D of regorafenib when given with temozolomide and radiotherapy in patients with MGMT-methylated, IDH wild-type glioblastoma was 120 mg.

Regorafenib Plus Temozolomide and RT Shows Early Signs of Tolerability in MGMT-Methylated, IDH Wild-Type Glioblastoma #SNO2025 #btsm #oncology www.onclive.com/view/regoraf...

Vorasidenib Plus Temozolomide Demonstrates Safety in IDH1/2+ Glioma | OncLive Vorasidenib plus temozolomide was safe in glioma harboring IDH1/2 mutations.

Vorasidenib Plus Temozolomide Demonstrates Safety in IDH1/2+ Glioma
@neuroonc.bsky.social #SNO2025 #oncology #braincancer #glioma
www.onclive.com/view/vorasid...

Exceptional #SNO2025 talk from UM
MSTP student @j-mitchell.bsky.social on the role of mitochondria transfer in GBM! Proud PI moment w/ @dionysioswatson.bsky.social 💪🏻

🚨 Today at #SNO2025 don’t miss the ASNO-EANO-SNO young investigator debates at 2:45 PM.
@neuroonc.bsky.social @eanoassociation.bsky.social #ArtificialIntelligence #NeuroOncology @mjlimfat.bsky.social @spyridonbakas.bsky.social @ph-lohmann.bsky.social

Susan Chang, MD, being presented with the 2025 Lisa DeAngelis Award for Excellence in Neuro-Oncology Education, on stage during the first plenary session of the conference.

A huge congratulations to Susan Chang, MD, for receiving the 2025 Lisa DeAngelis Award for Excellence in Neuro-Oncology Education! 🎉🥇The award recognizes her extraordinary impact on training the next generation of brain tumor researchers. #SNO2025 #WFNOS @neuroonc.bsky.social

Today at 2:45pm HST, @ranjitbindra.bsky.social
moderates Session 1 of Radiation Abstracts at #SNO2025.
virtual.oxfordabstracts.com/event/74646/...
@neuroonc.bsky.social

Starting today at #SNO2025, we have 5 exciting research posters being presented by Drs. Benjamin Lu, Elizabeth Claus
@yalesph.bsky.social, Jason Johnson, and Sylvia Kurz.
virtual.oxfordabstracts.com/event/74646/...
@neuroonc.bsky.social

Start of the Educational Day of #SNO2025 and WFNOS2025. Welcoming by @mjlimfat.bsky.social. Looking forward to an inspiring conference in Honolulu. @neuroonc.bsky.social @eanoassociation.bsky.social

Aloha from PeerView! 🌺

Join us at the Hilton Hawaiian Village tomorrow at 5:45 PM HST (10:45 PM EST) for our #SNO2025 MasterClass on IDH-mutant glioma with Drs. Ahluwalia & Cloughesy.

Register: https://bit.ly/2025Glioma-sky

#MedEd #Oncology

📣Attending WFNOS/ #SNO2025 this week? Don't miss the rapid oral & poster presentations by @eortc.org #QualityofLife Group member Ogechukwu A. Asogwa tomorrow & Saturday on health-related quality of life in molecular glioma subtypes 👇
www.soc-neuro-onc.org/SNO2025
#NeuroOncology @neuroonc.bsky.social

If you are at #SNO2025 be sure to check @milolab.bsky.social talks and posters including a keynote talk by @heilandhenrik.bsky.social #Hawaii🏖️🌊 #glioblastoma

“Disparities in Tumor Treating Fields (TTFields) Awareness, Access, and Patient Experience: Findings from a National GBM Survey” (Abstract DISP-34) Oral Session: Friday, November 21, 11:30am-12:30pm Poster Session: Saturday, November 22, 11:45am-1:05pm “Disparities in Glioblastoma Care: A National Survey on Access to Trials, Testing, and Informed Decision-Making” (Abstract QOL-35) Oral Presentation: Saturday, November 22, 4:30-5:30pm Selected for the 2025 Health Disparities & Quality Improvement Award

Visit our poster, attend a session, meet our Ex. Dir. Kelli Duprey, and learn about shocking disparities in GBM care in the USA.

Proud to be selected for the 2025 Health Disparities & Quality Improvement Award
#GBM #glioblastoma #GBMDisparities #SNO2025

At #SNO2025, learn how your company can collaborate with NBTS & connect with stakeholders from the drug development ecosystem to tackle urgent challenges in #braintumor research.